

Table S1. PubMed search strategy for North Carolina SARS-CoV-2 seroprevalence estimates

1	(Serology[Mesh] OR "Serologic Tests"[Mesh] OR Immunoglobulins[Mesh] OR "Seroepidemiologic Studies"[Mesh] OR sero*[tiab] OR antibody[tiab] OR "anti-body"[tiab] OR antibodies[tiab])
2	("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "COVID-19"[tiab] OR coronavirus[tiab] OR "covid 2019"[tiab] OR "SARS-CoV-2"[tiab] OR "severe acute respiratory syndrome coronavirus 2"[tiab])
3	"COVID-19 Serological Testing"[Mesh]
4	("North Carolina"[Mesh] OR "North Carolina"[tiab] OR "Charlotte"[tiab] OR "Raleigh"[tiab] OR "Greensboro"[tiab] OR "Durham"[tiab] OR "Winson-Salem"[tiab] OR "Fayetteville"[tiab] OR "Cary"[tiab] OR "Wilmington"[tiab])
5	(2019/12[Date - Publication]: 3000[Date - Publication])
6	((1 AND 2) OR 3) AND 4 AND 5

Note: 27 studies identified, none met all criteria or were not duplicates from SeroHub. Last date of search was October 16, 2023.

Table S2. SARS-CoV-2 infection-induced seroprevalence among the North Carolina general population by midpoint between collection start and end dates

Study	Population description	Assay	Collection dates (year-month-day)	Sample size	Infection-induced seroprevalence, % (95% CI)
Barzin, 2020	Inpatients unrelated to COVID-19	Abbot Architect N	2020-03-03 to 2020-06-04	1449	0.7
Barzin, 2020	Asymptomatic people at NC outpatient clinics	Abbot Architect N	2020-04-28 to 2020-06-19	2973	0.8
COVID-19 Community Research Partnership Study Group, 2021	Wake Forest Baptist Health and Atrium Health systems, general pop	Syntron/Tianjin New Bay Bioresearch N lateral flow assay (LFA)	2020-04-16 to 2021-01-04	11468	10.2
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-02-08 to 2021-02-18	1309	20.6 (18.3,23)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-02-01 to 2021-02-28	4208	16.4 (14.6,18.5)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-02-22 to 2021-03-01	1172	22.5 (19.8,25)

CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-03-09 to 2021-03-18	1140	23.8 (21.1,26.6)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-03-01 to 2021-03-31	4072	18 (16.2,19.8)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-03-24 to 2021-03-31	1362	22.9 (20.5,25.6)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-04-05 to 2021-04-14	1304	23 (20.2,25.6)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-04-01 to 2021-04-30	4195	20 (17.9,22.3)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-04-19 to 2021-04-28	1303	21.9 (19.2,24.6)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-05-03 to 2021-05-12	1307	24.4 (22.1,27)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-05-01 to 2021-05-31	4159	19.5 (17.8,21.2)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-05-17 to 2021-05-29	1272	22.7 (20.1,25.6)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-05-31 to 2021-06-09	1268	23.8 (21.1,26.4)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-06-01 to 2021-06-30	4157	18 (16,20.1)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-06-14 to 2021-06-25	1315	22.8 (20.2,25.3)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-06-28 to 2021-07-09	1302	22.6 (20,25.2)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-07-01 to 2021-07-31	4168	18.7 (16.6,21.1)
CDC blood donor surveillance	Central and Western NC region blood donors	Roche Elecsys N	2021-08-01 to 2021-08-31	4226	20.7 (18.6,22.9)
CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminescent total Ig N, Ortho Clinical Diagnostics	2021-09-01 to 2021-09-30	4312	23.6 (22,25.3)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-09-06 to 2021-10-02	1767	26.6 (24.2,29.1)

CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminescent total Ig N, Ortho Clinical Diagnostics	2021-10-01 to 2021-10-31	4330	25 (22.9,27.1)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-10-04 to 2021-10-30	1775	33.6 (30.7,36.5)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-11-01 to 2021-11-24	1846	30.3 (27.7,33)
CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminescent total Ig N, Ortho Clinical Diagnostics	2021-11-01 to 2021-11-30	4311	27.7 (25.7,29.6)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2021-11-29 to 2021-12-22	1833	34.5 (32.1,37.2)
CDC blood donor surveillance	Central and Western NC region blood donors	VITROS chemiluminescent total Ig N, Ortho Clinical Diagnostics	2021-12-01 to 2021-12-31	4071	28.1 (26.1,30)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2022-01-03 to 2022-01-20	1329	40 (36.7,43.4)
CDC commercial lab surveillance	NC commercial lab remnant specimens	Roche Elecsys N	2022-02-01 to 2022-02-18	1317	52 (48.9,55.2)

Note: estimates overlapping with Animal Slaughtering and Processing industry enrollment (April 2, 2021 to July 28, 2022) are highlighted in grey. The minimum prevalence estimate overlapping with Animal Slaughtering and Processing industry enrollment (April 2, 2021 to July 28, 2022) was 18% and maximum 52%.

Table S3. Source of information (multiplex antibody and questionnaire data) for determining evidence of prior SARS-CoV-2 infection among adult (≥ 18) participants (N=236), concordant multiplex N/S and synthesis results highlighted green (n=220)

Questionnaire responses	Multiplex salivary SARS-CoV-2 IgG antibody assay results	Synthesis of antibody assay results and reported viral test and vaccination history	n

Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	N/S	Evidence of prior infection	26
Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	S	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	≥1 vaccine dose	Unknown	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	No vaccine	N/S	Evidence of prior infection	9
Ever positive viral SARS-CoV-2 test	No vaccine	none	Evidence of prior infection	2
Ever positive viral SARS-CoV-2 test	No vaccine	Unknown	Evidence of prior infection	3
Ever positive viral SARS-CoV-2 test	Unknown	N/S	Evidence of prior infection	1
No positive viral SARS-CoV-2 test	≥1 vaccine dose	N/S	Evidence of prior infection	26
No positive viral SARS-CoV-2 test	No vaccine	N/S	Evidence of prior infection	16
No positive viral SARS-CoV-2 test	No vaccine	S	Evidence of prior infection	1
Unknown	≥1 vaccine dose	N/S	Evidence of prior infection	20
Unknown	No vaccine	N/S	Evidence of prior infection	29
Unknown	No vaccine	S	Evidence of prior infection	6
Unknown	Unknown	N/S	Evidence of prior infection	1
No positive viral SARS-CoV-2 test	≥1 vaccine dose	S	No evidence of prior infection	27
No positive viral SARS-CoV-2 test	≥1 vaccine dose	none	No evidence of prior infection	6
No positive viral SARS-CoV-2 test	No vaccine	none	No evidence of prior infection	16
No positive viral SARS-CoV-2 test	Unknown	S	No evidence of prior infection	1
No positive viral SARS-CoV-2 test	Unknown	none	No evidence of prior infection	2
Unknown	≥1 vaccine dose	S	No evidence of prior infection	13
Unknown	≥1 vaccine dose	none	No evidence of prior infection	1
Unknown	No vaccine	none	No evidence of prior infection	26

Note: of 236 adult participants, 128 were positive for any evidence of prior SARS-CoV-2 infection and N/S IgG; 92 were negative for any evidence of infection and N/S IgG; 11 were positive for evidence of infection and negative for N/S IgG; and 5 were positive for any evidence of infection and invalid for N/S IgG. Of 167 employed adult participants, 93 were positive for any

evidence of prior SARS-CoV-2 infection and N/S IgG; 65 were negative for any evidence of infection and N/S IgG; 5 were positive for evidence of infection and negative for N/S IgG; and 4 were positive for any evidence of infection and invalid for N/S IgG.

Table S4. PubMed search strategy for US animal slaughtering and processing worker SARS-CoV-2 seroprevalence estimates

1	(Serology[Mesh] OR "Serologic Tests"[Mesh] OR Immunoglobulins[Mesh] OR "Seroepidemiologic Studies"[Mesh] OR sero*[tiab] OR antibody[tiab] OR "anti-body"[tiab] OR antibodies[tiab])
2	("COVID-19"[Mesh] OR "SARS-CoV-2"[Mesh] OR "COVID-19"[tiab] OR "covid 2019"[tiab] OR "SARS-CoV-2"[tiab] OR "severe acute respiratory syndrome coronavirus 2"[tiab])
3	"COVID-19 Serological Testing"[Mesh]
4	("Meat-Packing Industry"[Mesh] OR "Poultry"[Mesh] OR "Cattle"[Mesh] OR "Swine"[Mesh] OR "meat pack*" [tiab] OR meatpack*[tiab] OR "meat process*" [tiab] OR slaughterer*[tiab] OR cutter*[tiab] OR meat[tiab] OR poultry[tiab] OR cattle[tiab] OR swine[tiab])
5	("Occupational Groups"[Mesh] OR "Work"[Mesh] OR "Workplace"[Mesh] OR work*[tiab] OR occupation*[tiab] OR industry*[tiab])
6	(2019/12[Date - Publication]: 3000[Date - Publication])
7	((1 AND 2) OR 3) AND 4 AND 5 AND 6

Note: 20 studies identified, only 1 relevant and carried out in the US. Last date of search was December 14, 2023.

Table S5. Workplace characteristics and infection prevention and control measures by industry among adult (≥ 18) employed participants (N=167), North Carolina, 2021-2022

Characteristic, n (%)	Animal slaughtering & processing, N = 57	Health care & social assistance, N = 20	Animal production & aquaculture, N = 13	Other, N = 77	p-value for any difference
Essential worker	56 (98%)	16 (80%)	13 (100%)	39 (52%)	<0.001 ^a
Worked in person past 2 weeks (at all)	57 (100%)	20 (100%)	13 (100%)	62 (81%)	<0.001 ^a
Employees at worksite					
10 or fewer	5 (8.8%)	7 (39%)	9 (69%)	22 (31%)	

11-100	10 (18%)	8 (44%)	3 (23%)	27 (38%)	
101-1000	21 (37%)	1 (5.6%)	1 (7.7%)	20 (28%)	
>1000	21 (37%)	2 (11%)	0 (0%)	2 (2.8%)	
Hours worked per week					<0.001 ^a
<40	1 (1.8%)	5 (25%)	3 (23%)	26 (34%)	
40	17 (30%)	12 (60%)	2 (15%)	21 (27%)	
>40	39 (68%)	3 (15%)	8 (62%)	30 (39%)	
Aware of COVID-19 cases at work past 2 weeks	49 (86%)	16 (80%)	10 (83%)	68 (88%)	0.7 ^a
Able to maintain 6+ feet of distance	42 (75%)	12 (60%)	12 (92%)	61 (79%)	0.2 ^a
Could isolate if COVID-19+	51 (96%)	20 (100%)	10 (77%)	70 (93%)	0.078 ^a
Could quarantine if COVID-19 exposed	49 (92%)	20 (100%)	11 (85%)	72 (96%)	0.2 ^a
<i>Infection prevention and control measures</i>					
<i>Engineering controls</i>					
Physical barriers between stations	18 (32%)	6 (30%)	2 (15%)	28 (36%)	0.5 ^a
Added hand washing stations	44 (77%)	14 (70%)	9 (69%)	47 (61%)	0.3 ^a
<i>Administrative controls</i>					
Change in workplace sick leave	12 (21%)	12 (60%)	1 (7.7%)	23 (30%)	0.004 ^a
COVID-19 testing at work	29 (51%)	11 (55%)	2 (15%)	16 (21%)	<0.001 ^a
Masks required	50 (88%)	18 (90%)	7 (54%)	55 (71%)	0.011 ^a
<i>PPE</i>					
Employer provides face masks (any type)	53 (93%)	18 (90%)	7 (54%)	63 (82%)	0.007 ^a
Employer provides N95/KN96/respirators	9 (16%)	7 (35%)	4 (31%)	13 (17%)	0.2 ^a
Employer provides surgical masks	36 (63%)	16 (80%)	4 (31%)	42 (55%)	0.030 ^b
Employer provides cloth masks	28 (49%)	4 (20%)	0 (0%)	33 (43%)	0.003 ^b
Employer provides face shields	28 (49%)	7 (35%)	3 (23%)	14 (18%)	0.001 ^a
Employer provides hand protection	44 (77%)	12 (60%)	7 (54%)	23 (30%)	<0.001 ^b

^a Fisher's exact test for any difference in characteristic among industry categories

^b Pearson's Chi-squared test for any difference in characteristic among industry categories